INTRODUCTION
considered in patients when residual stenosis of more than 50%, with elastic recoil or with complication. Patients were monitored for any post-procedure complications such as bleeding, access site hematoma or access thrombosis. Patients were allowed to use accesses soon after the procedure, if needed. Patients were followed in vascular surgery clinics at 3-month interval.
The outcomes measured were symptomatic recovery and improvement in the patency of arteriovenous access. Symptomatic recovery was termed 'complete', when there was complete symptomatic relief after venoplasty; and 'partial' when the procedure was technically successful but symptoms that led to venoplasty, were not resolved.
Patency of AV accesses were measured as primary and cumulative patency. Primary patency was the duration of time from first intervention to next intervention or fistula failure. Cumulative patency was the total duration of time fistula remain, patent with multiple interventions.
Events considered end points to functional access status were placement of new access site, ligation of access site, dialysis catheter placement or the patient death.
Categorical variables were reported as frequencies along with their percentages. Continuous variables were reported as mean ± standard deviation. Patency rate was calculated using Kaplan-Meier survival curve. A p-value of <0.05 was considered as significant. Analyses were performed using SPSS version 22 (IBM Inc.).
RESULTS
During the study period, 48 patients had attempted venoplasty. Thirteen patients were excluded as wire was not negotiable through the lesion. Thirty-five patients had technically successful venoplasty. The mean age of the patients was 56.86 ±14.6 years. Most of them were females (21, 60%). The major comorbidities were hypertension and diabetes (Table I) . Twenty-four (68.6%) patients had native arteriovenous fistula, while 11 (31.4%) had arteriovenous grafts.
Twenty-three (65.7%) patients presented with arm swelling, 10 (28.6%) patients with poor flow, and 2 (5.7%) patients with increased pressure during dialysis.
The most common sites of stenosis were brachiocephalic vein followed by subclavian vein. One patient had balloon leak, while another patient had cardiac event in post-procedure day, which settled with medical management.
Twenty-one (60%) patients had initial complete relief of symptoms and 14 (40%) patients had partial relief. Primary patency was 40%, 24%, 24% at 6, 12 and 24 months. Cumulative patency was 69%, 66% and 59% at 6, 12 and 24 months (Figures 1 and 2 ). Twenty-six (74%) patients had recurrence of symptoms. Twenty-one (60%) patients underwent repeat angioplasty. Five patients (14%) had surgical management for CVS. Ligation and formation of new AVF in one patient; two patients had thrombectomies, while two patients had bypass procedures for relieving CVS. Four patients had stents placed. One stent was placed at the time of first angioplasty and three were placed at the time of the repeated venoplasty sessions.
DISCUSSION
The present study showed that CVS venoplasty improved patients' symptoms and also improved the short term patency of vascular access. Seventy-four percent patients had recurrence in which most patients required repeated venoplasty. There were no major complication encountered. All accesses were usable for dialysis soon after the procedure.
Bakken et al. showed improved haemodialysis access patency of 77%, 73% and 57% at 3, 12 and 24 months after CVS venoplasty. 8 Bountouris et al. also noted patency of 42% at 24 months. 9 Glanz S et al. noted 1-year patency rate of 35%. 10 The results are consistent with this study. Ya et al. showed, PTA for CVC achieved technical success in 92% of cases, and symptoms were initially alleviated in 96% of subjects. 11 Others have also documented the efficiency of this modality. 12 The authors also found it effective in relieving patients arm swelling.
Many authors have highlighted the issue of recurrence after initial venoplasty and considered it a norm. Ya et al.
showed recurrence rate of 58% at 4 months after PTA. 11 Same were the findings of the Sprouse et al. and Argarwal et al. 13, 14 Inflating the balloon itself caused local intimal injury and may induce neointimal hyperplasia, hence recurrent venous stenosis.
Plain balloons were used but better patency may be achievable with cutting balloons, 15 drug-eluting balloons, 16 or specialised high pressure balloons. These were neither available nor feasible due to higher cost.
The use of stents is controversial during intervention. Many of the previous studies fail to demonstrate whether stenting provides additional benefit or not. Stents were offered only to those patients who had elastic recoil or had significant persistent stenosis. There have been studies which document better patency rates following stenting. However, long term patency is not seen in all cases. Quinn et al. compared stenting with PTA alone and saw that patency rates were comparative in both cases. 17 Oderich et al. reported that primary patency remains same at one year and re-intervention rate is not better than the presently reported results. 18 The limitations of this study include being a retrospective, collection of data from a single institute with limited number of patients. Despite this, it showed the efficiency of PTA in relieving arm oedema and improving short term longevity of AV accesses.
CONCLUSION
Percutaneous venoplasty for CVS can provide symptomatic relief in majority of the patients and can improve the short term patency of arteriovenous access.
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